Consumer UK is an IP holding entity and is into the business of sale and distribution of pharmaceutical and other over-the-counter consumer health care products, through its subsidiaries in US and India.

Strides Pharma Science announces acquisition of balance stake in Strides Global Consumer Healthcare, UK

Strides Pharma Q1 Earnings Update: What's The Strategy Of Company For Future Growth Of Business?

As per the company statement, US revenues for Strides in Q1 FY25 stood at a quarter-high of $70 million (about Rs 586 crore)

Strides Pharma reports profit of Rs 68.3 crore in Q1, revenue up 16%

Consequent to above, the paid-up share capital of the Company has increased from Rs. 91,91,67,140/- consisting of 9,19,16,714 equity shares of Rs. 10/- each to Rs. 91,95,82,140/-consisting of 9,19,58,214 equity shares of Rs. 10/- each.

Strides Pharma Science allots 41,500 equity shares under ESOP

Strides Pharma Science added 2.46% to Rs 1,053.75 after the company reported a consolidated net profit of Rs 70.20 crore in Q1 FY25 as against a net loss of Rs 7.11 crore posted in Q1 FY24.

Strides Pharma hits 52-week high on reporting turnaround Q1 performance

Strides Pharma Science reports consolidated net profit of Rs 70.20 crore in the June 2024 quarter

Buzzing Stocks Today, Stocks that will see action today: 29 July 2024 - UltraTech Cement, India Cements, Maruti Suzuki, Manappuram Finance, Colgate Palmolive, Cipla, Biotin, Strides Pharma, Glenmark Life, Cholamandalam Finance, Indoco Remedies, BHEL, Godawari Power, Hindustan Zinc, Jubilant Pharmova, Laxmi Organic

Stock that will see action today: July 29, 2024

Strides New Zealand shall hold market authorizations for the products in New Zealand and shall also undertake trading in pharmaceutical products.

Strides Pharma Global, Singapore incorporates subsidiary in New Zealand

Lauras Labs price has broken out from downward sloping trend line on the weekly chart. Price rise was accompanied by healthy volumes

Lauras Labs, Strides Pharma: Top picks by Vinay Rajani to buy on July 18

Strides Pharma has retraced more than 61.8 per cent of the entire fall which was seen from the swing high of Rs 425 towards the recent swing low of Rs 312, which indicates negation of a down trend

Buy & Sell Ideas for June 19; check top stock picks by HDFC Securities

“Strides Pharma Science stock on the daily chart has broken out of its range-bound movement, where it had been trading for several days. Traders can buy for a target of Rs 1010-1150 in the next 3-4 weeks,” says KKunal V Parar, Vice-President of Technical Research and Algo, Choice Broking.

► Subscribe to The Economic Times for the latest video updates. It's free! - https://www.youtube.com/TheEconomicTimes?sub_confirmation=1

► More Videos @ ETTV - https://economictimes.indiatimes.com/TV

► https://EconomicTimes.com

► For business news on the go, download ET app:
https://etapp.onelink.me/tOvY/EconomicTimesApp

Follow ET on:

► Facebook - https://www.facebook.com/EconomicTimes 
► Twitter - https://www.twitter.com/economictimes
► LinkedIn - https://www.linkedin.com/company/economictimes
► Instagram - https://www.instagram.com/the_economic_times
► Flipboard - https://flipboard.com/@economictimes

#news #latestnews #economictimes #ET #TheEconomicTimes #businessnews

Stock Radar | Strides Pharma stock bounces back after retesting 50-DMA on daily charts

Price return has been average, nothing exciting

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is underpriced and is not in the overbought zone

Current price is less than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Strides Pharma Science is a vertically integrated global pharmaceutical company engaged in the development and manufacturing of active pharmaceutical ingredients and formulations, as well as biotech